{"schema_version":"1","generated_at":"2026-11-20T13:35:58.495Z","data_as_of":null,"url":"https://www.findmykol.com/kol/donald-eagerton","json_url":"https://www.findmykol.com/kol/donald-eagerton/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"donald-eagerton","name":"Donald Eagerton","credential":"MD","specialty":"Endocrinology, Diabetes & Metabolism","specialty_raw":"Endocrinology, Diabetes & Metabolism","therapeutic_area":"Endocrinology/Metabolic","therapeutic_areas":["Endocrinology/Metabolic"],"institution":"Strand Physician Specialists","institution_url":"https://www.findmykol.com/institution/strand-physician-specialists","city":"Myrtle Beach","state":"SC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Donald Eagerton is an Endocrinology/Metabolic physician affiliated with Strand Physician Specialists. OpenAlex indexes 16 publications with 2,816 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Endocrinology/Metabolic"]},"scholarship":{"works_count":16,"cited_by_count":2816,"h_index":10,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":64,"program_years":{"first":2021,"last":null},"rows_total":161,"shown":3,"withheld":158,"rows":[{"payer":"Moderna","program_year":2025,"amount_usd":795869.49,"payment_count":74},{"payer":"Eli Lilly","program_year":2025,"amount_usd":277115.96,"payment_count":5},{"payer":"Boehringer Ingelheim","program_year":2025,"amount_usd":60211.85,"payment_count":58}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":10,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":32.5,"classes_total":2,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":32.5,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":13},{"class":"P2Y12 inhibitor","setting":"prescribed","share_pct":0,"drugs":[{"name":"Clopidogrel","share_pct":100}],"max_beneficiaries":null}]},{"area":"Musculoskeletal","share_pct":31.4,"classes_total":4,"classes":[{"class":"Other drugs affecting bone structure and mineralization","setting":"administered","share_pct":22.8,"drugs":[{"name":"Romosozumab-aqqg","share_pct":100}],"max_beneficiaries":27},{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":7.3,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":59}]},{"area":"Cardiovascular","share_pct":25.5,"classes_total":14,"classes":[{"class":"Other lipid modifying agents","setting":"mixed","share_pct":22.2,"drugs":[{"name":"Inclisiran","share_pct":99.8},{"name":"Icosapent Ethyl","share_pct":0.2}],"max_beneficiaries":null},{"class":"Statin","setting":"prescribed","share_pct":1.7,"drugs":[{"name":"Atorvastatin Calcium","share_pct":44.1},{"name":"Rosuvastatin Calcium","share_pct":38.3},{"name":"Pravastatin Sodium","share_pct":9.7},{"name":"Simvastatin","share_pct":7.9}],"max_beneficiaries":121}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.9,"facility_pct":0.1},"source":"medicare"},"publications":{"total":16,"shown":5,"withheld":11,"matched_by":"OpenAlex author record","recent":[{"title":"Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes","year":2026,"journal":"JAMA Internal Medicine","source_url":"https://doi.org/10.1001/jamainternmed.2025.7774","status":"verified"},{"title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes","year":2026,"journal":"JAMA Cardiology","source_url":"https://doi.org/10.1001/jamacardio.2026.0245","status":"verified"},{"title":"Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES","year":2025,"journal":"Circulation","source_url":"https://doi.org/10.1161/circulationaha.124.071269","status":"verified"},{"title":"Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial","year":2025,"journal":"Diabetes Care","source_url":"https://doi.org/10.2337/dc25-1080","status":"verified"},{"title":"SAT-784 The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures","year":2025,"journal":"Journal of the Endocrine Society","source_url":"https://doi.org/10.1210/jendso/bvaf149.637","status":"verified"}],"source":"works"},"similar":[{"name":"Douglas Conaway","slug":"douglas-conaway","institution":"Strand Physician Specialists","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/douglas-conaway","json_url":"https://www.findmykol.com/kol/douglas-conaway/profile.json"},{"name":"Yousef Saleh Khader","slug":"yousef-khader","institution":"Jordan University of Science and Technology","url":"https://www.findmykol.com/kol/yousef-khader","json_url":"https://www.findmykol.com/kol/yousef-khader/profile.json"},{"name":"Jens Juul Holst","slug":"jens-holst","institution":"University of Copenhagen","url":"https://www.findmykol.com/kol/jens-holst","json_url":"https://www.findmykol.com/kol/jens-holst/profile.json"},{"name":"Victor Montori","slug":"victor-montori","institution":"Mayo Clinic","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/victor-montori","json_url":"https://www.findmykol.com/kol/victor-montori/profile.json"},{"name":"Christos Mantzoros","slug":"christos-mantzoros","institution":"Harvard Medical School","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/christos-mantzoros","json_url":"https://www.findmykol.com/kol/christos-mantzoros/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":158,"publications":11}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}